Lastly, ICI therapy-associated atherosclerosis has provided additional insights into the potential risk factors for anti-PD-L1 therapy or combined anti-PD-L1 and anti-CTLA4 therapy. This evidence concerns the gene CTLA4 and atherosclerosis.